PT2376533T - Formulação de anticorpos - Google Patents

Formulação de anticorpos

Info

Publication number: PT2376533T
Authority: PT; Portugal
Prior art keywords: antibodies; formulation
Prior art date: 2008-12-10

Application number

PT97648588T

Other languages

English (en)

Inventor

Momm Joachim

Wallny Hans-Joachim

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-12-10

Filing date

2009-12-09

Publication date

2016-07-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40637230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2376533(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-12-09 Application filed by Novartis Ag filed Critical Novartis Ag

2016-07-13 Publication of PT2376533T publication Critical patent/PT2376533T/pt

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Mycology (AREA)
Dermatology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Inorganic Chemistry (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

PT97648588T 2008-12-10 2009-12-09 Formulação de anticorpos PT2376533T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP08170884A EP2196476A1 (en)	2008-12-10	2008-12-10	Antibody formulation

Publications (1)

Publication Number	Publication Date
PT2376533T true PT2376533T (pt)	2016-07-13

Family

ID=40637230

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT161626999T PT3072906T (pt)	2008-12-10	2009-12-09	Formulação de anticorpos
PT97648588T PT2376533T (pt)	2008-12-10	2009-12-09	Formulação de anticorpos

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT161626999T PT3072906T (pt)	2008-12-10	2009-12-09	Formulação de anticorpos

Country Status (31)

Country	Link
US (3)	US20110236398A1 (pt)
EP (4)	EP2196476A1 (pt)
JP (6)	JP6143416B2 (pt)
KR (2)	KR101762966B1 (pt)
CN (3)	CN104399076B (pt)
AU (1)	AU2009324371B2 (pt)
BR (1)	BRPI0922730A2 (pt)
CA (1)	CA2745938C (pt)
CL (1)	CL2011001406A1 (pt)
CO (1)	CO6361952A2 (pt)
CY (2)	CY1117735T1 (pt)
DK (2)	DK2376533T3 (pt)
EC (1)	ECSP11011192A (pt)
ES (2)	ES2579835T3 (pt)
HR (2)	HRP20160754T1 (pt)
HU (2)	HUE028408T2 (pt)
IL (3)	IL264316B2 (pt)
LT (1)	LT3072906T (pt)
MA (1)	MA33023B1 (pt)
MX (1)	MX2011006242A (pt)
MY (2)	MY157772A (pt)
NZ (1)	NZ592918A (pt)
PE (1)	PE20120342A1 (pt)
PL (2)	PL3072906T3 (pt)
PT (2)	PT3072906T (pt)
RU (2)	RU2745601C2 (pt)
SI (2)	SI3072906T1 (pt)
SM (1)	SMT201600222B (pt)
TN (1)	TN2011000229A1 (pt)
WO (1)	WO2010066762A1 (pt)
ZA (1)	ZA201103362B (pt)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2196476A1 (en) *	2008-12-10	2010-06-16	Novartis Ag	Antibody formulation
US8221753B2 (en)	2009-09-30	2012-07-17	Tracon Pharmaceuticals, Inc.	Endoglin antibodies
EP3409289B1 (en)	2010-02-26	2020-09-30	Novo Nordisk A/S	Stable antibody containing compositions
RS59830B1 (sr)	2010-03-01	2020-02-28	Bayer Healthcare Llc	Optimizovana monoklonska antitela protiv inhibitora puta faktora tkiva (tfpi)
RU2012153786A (ru)	2010-05-28	2014-07-10	Ново Нордиск А/С	Стабильные многодозовые композиции, содержащие антитело и консервант
AR082319A1 (es) *	2010-07-22	2012-11-28	Biomarin Pharm Inc	Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
CA2807552A1 (en)	2010-08-06	2012-02-09	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
EA032336B1 (ru)	2010-09-17	2019-05-31	Баксалта Инкорпорейтид	Стабильная водная иммуноглобулиновая композиция и способ стабилизации иммуноглобулиновой композиции
ES3005233T3 (en)	2010-10-01	2025-03-14	Modernatx Inc	Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
TWI719112B (zh)	2011-03-16	2021-02-21	賽諾菲公司	雙重ｖ區類抗體蛋白質之用途
JP2014511687A (ja)	2011-03-31	2014-05-19	モデルナセラピューティクスインコーポレイテッド	工学操作された核酸の送達および製剤
US9464124B2 (en)	2011-09-12	2016-10-11	Moderna Therapeutics, Inc.	Engineered nucleic acids and methods of use thereof
EP2763701B1 (en)	2011-10-03	2018-12-19	Moderna Therapeutics, Inc.	Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
FI123630B (fi)	2011-10-24	2013-08-30	Teknologian Tutkimuskeskus Vtt	Menetelmä NFC-kalvojen valmistamiseksi alustoille
AP2014007680A0 (en)	2011-12-02	2014-06-30	Novartis Ag	Anti-1L-beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
JP2015501844A (ja)	2011-12-16	2015-01-19	モデルナセラピューティクスインコーポレイテッドＭｏｄｅｒｎａＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	修飾ヌクレオシド、ヌクレオチドおよび核酸組成物
ES2732243T3 (es) *	2012-02-16	2019-11-21	Santarus Inc	Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
KR102213535B1 (ko) *	2012-03-16	2021-02-08	리제너론 파마슈티칼스 인코포레이티드	pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물
US9254311B2 (en)	2012-04-02	2016-02-09	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of proteins
US9283287B2 (en)	2012-04-02	2016-03-15	Moderna Therapeutics, Inc.	Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en)	2012-04-02	2017-02-21	Modernatx, Inc.	Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151663A1 (en)	2012-04-02	2013-10-10	modeRNA Therapeutics	Modified polynucleotides for the production of membrane proteins
US8883979B2 (en) *	2012-08-31	2014-11-11	Bayer Healthcare Llc	Anti-prolactin receptor antibody formulations
US9592297B2 (en)	2012-08-31	2017-03-14	Bayer Healthcare Llc	Antibody and protein formulations
US8613919B1 (en)	2012-08-31	2013-12-24	Bayer Healthcare, Llc	High concentration antibody and protein formulations
UA115789C2 (uk)	2012-09-05	2017-12-26	Трейкон Фармасутікалз, Інк.	Композиція антитіла до cd105 та її застосування
EP3916013A1 (en)	2012-09-20	2021-12-01	MorphoSys AG	Treatment for rheumatoid arthritis with anti-gm-csf antibody
AU2013344796B2 (en) *	2012-11-16	2016-11-10	Novartis Ag	Use of IL-1 beta binding antibodies for treating peripheral arterial disease
ES2921623T3 (es)	2012-11-26	2022-08-30	Modernatx Inc	ARN modificado terminalmente
US8980864B2 (en)	2013-03-15	2015-03-17	Moderna Therapeutics, Inc.	Compositions and methods of altering cholesterol levels
JP2016515515A (ja)	2013-03-15	2016-05-30	バイエル・ヘルスケア・エルエルシーＢａｙｅｒＨｅａｌｔｈＣａｒｅＬＬＣ	抗プロラクチン受容体抗体製剤
TWI679019B (zh)	2013-04-29	2019-12-11	法商賽諾菲公司	抗ｉｌ－４／抗ｉｌ－１３之雙特異性抗體調配物
NL1040254C2 (en) *	2013-05-17	2014-11-24	Ablynx Nv	Stable formulations of immunoglobulin single variable domains and uses thereof.
WO2015048744A2 (en)	2013-09-30	2015-04-02	Moderna Therapeutics, Inc.	Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko)	2013-10-03	2016-06-13	모더나 세라퓨틱스, 인코포레이티드	저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2015181757A1 (en) *	2014-05-28	2015-12-03	Nono Inc.	Lyophilized formulation of tat-nr2b9c with acetylation scavenger
AU2015310879A1 (en) *	2014-09-03	2017-03-02	Medimmune Limited	Stable anti-IL-4R-alpha antibody formulation
US9926375B2 (en)	2014-11-12	2018-03-27	Tracon Pharmaceuticals, Inc.	Anti-endoglin antibodies and uses thereof
WO2016077451A1 (en)	2014-11-12	2016-05-19	Tracon Pharmaceuticals, Inc.	Anti-endoglin antibodies and uses thereof
AR103173A1 (es)	2014-12-22	2017-04-19	Novarits Ag	Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
AR104847A1 (es)	2015-06-17	2017-08-16	Lilly Co Eli	Formulación de anticuerpo anti-cgrp
CN108367072B (zh)	2015-12-07	2022-12-27	默克专利股份有限公司	含抗-pd-l1抗体avelumab的水性药物制剂
CN109415440B (zh) *	2016-06-27	2022-12-06	莫佛塞斯公司	抗-cd19抗体制剂
KR20190032436A (ko) *	2016-07-21	2019-03-27	노파르티스 아게	폐 유육종증의 증상을 치료하거나 완화하기 위한 il-1beta 결합 항체 카나키누맙의 용도
AU2017333367A1 (en) *	2016-09-27	2019-04-04	Fresenius Kabi Deutschland Gmbh	Liquid pharmaceutical composition
MY195529A (en)	2016-11-18	2023-01-30	Astellas Pharma Inc	Novel Anti-Human MUC1 Antibody Fab Fragment
US20190048072A1 (en) *	2017-06-22	2019-02-14	Novartis Ag	USE OF IL-1beta BINDING ANTIBODIES
TWI795415B (zh)	2017-07-07	2023-03-11	日商安斯泰來製藥股份有限公司	新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
US20200207848A1 (en) *	2017-09-13	2020-07-02	Novartis Ag	Use of il-1b binding antibodies for the treatment of alcoholic hepatitis
TW202003036A (zh) *	2018-03-23	2020-01-16	德商艾伯維德國有限及兩合公司	穩定水性抗-tau抗體調配物
WO2019221269A1 (ja)	2018-05-17	2019-11-21	アステラス製薬株式会社	抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体
MY205764A (en) *	2018-10-10	2024-11-12	Astellas Pharma Inc	Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
SG11202108627SA (en) *	2019-02-18	2021-09-29	Lilly Co Eli	Therapeutic antibody formulation
CN113967195A (zh) *	2020-07-22	2022-01-25	三生国健药业（上海）股份有限公司	抗her2/pd1双特异性抗体冻干制剂及其制备方法
US20240052026A1 (en) *	2020-12-22	2024-02-15	Bio-Thera Solutions, Ltd.	Stable antibody formulation, preparation method therefor, and applications thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1995001997A1 (en)	1993-07-09	1995-01-19	Smithkline Beecham Corporation	RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
PE64396A1 (es)	1995-01-23	1997-01-28	Hoffmann La Roche	Proteina accesoria del receptor de la interleucina 1
CA2226575C (en)	1995-07-27	2011-10-18	Genentech, Inc.	Stabile isotonic lyophilized protein formulation
US6171586B1 (en) *	1997-06-13	2001-01-09	Genentech, Inc.	Antibody formulation
GB0001662D0 (en)	1999-02-06	2000-03-15	Zeneca Ltd	Pharmaceutical compositions
TW200528436A (en)	1999-09-22	2005-09-01	Bristol Myers Squibb Co	Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
MXPA02012867A (es)	2000-06-29	2003-09-05	Abbott Lab	Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos.
JP5490972B2 (ja) *	2000-08-04	2014-05-14	中外製薬株式会社	タンパク質注射製剤
GB0020685D0 (en) *	2000-08-22	2000-10-11	Novartis Ag	Organic compounds
ES2392073T3 (es) *	2001-11-08	2012-12-04	Abbott Biotherapeutics Corp.	Formulación farmacéutica líquida estable de anticuerpos IGG
US7132100B2 (en) *	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
AU2004229335C1 (en) *	2003-04-04	2010-06-17	Genentech, Inc.	High concentration antibody and protein formulations
KR20070107079A (ko) *	2005-01-28	2007-11-06	와이어쓰	안정화된 액체 폴리펩타이드 제형
GT200600031A (es) *	2005-01-28	2006-08-29		Formulacion anticuerpo anti a beta
LT2620450T (lt) *	2005-03-08	2019-02-11	Pfizer Products Inc.	Anti-ctla-4 antikūnų kompozicijos
EP1888637A2 (en) *	2005-05-19	2008-02-20	Amgen Inc.	Compositions and methods for increasing the stability of antibodies
EP2848258B1 (en)	2005-10-26	2017-12-13	Novartis AG	Treatment of familial Mediterranean Fever with anti IL-1beta antibodies
CN201044845Y (zh) *	2006-10-28	2008-04-09	李开元	自动注射器
CN101553504A (zh) *	2006-12-11	2009-10-07	豪夫迈·罗氏有限公司	Aβ抗体胃肠外制剂
MX2009010179A (es) *	2007-03-22	2010-03-15	Imclone Llc	Formulaciones estables de anticuerpo.
EP2196476A1 (en) *	2008-12-10	2010-06-16	Novartis Ag	Antibody formulation
WO2010100179A2 (en)	2009-03-05	2010-09-10	Novartis Ag	Self-forming gel system for sustained drug delivery
WO2012028683A1 (en)	2010-09-02	2012-03-08	Novartis Ag	Antibody gel system for sustained drug delivery

2008
- 2008-12-10 EP EP08170884A patent/EP2196476A1/en not_active Ceased
2009
- 2009-12-09 PT PT161626999T patent/PT3072906T/pt unknown
- 2009-12-09 CN CN201410730219.7A patent/CN104399076B/zh active Active
- 2009-12-09 MY MYPI2011002067A patent/MY157772A/en unknown
- 2009-12-09 ES ES09764858.8T patent/ES2579835T3/es active Active
- 2009-12-09 US US13/133,843 patent/US20110236398A1/en not_active Abandoned
- 2009-12-09 SI SI200932153T patent/SI3072906T1/sl unknown
- 2009-12-09 JP JP2011540063A patent/JP6143416B2/ja active Active
- 2009-12-09 CA CA2745938A patent/CA2745938C/en active Active
- 2009-12-09 BR BRPI0922730-0A patent/BRPI0922730A2/pt not_active Application Discontinuation
- 2009-12-09 EP EP16162699.9A patent/EP3072906B1/en active Active
- 2009-12-09 MX MX2011006242A patent/MX2011006242A/es active IP Right Grant
- 2009-12-09 HU HUE09764858A patent/HUE028408T2/en unknown
- 2009-12-09 EP EP09764858.8A patent/EP2376533B1/en active Active
- 2009-12-09 RU RU2015132431A patent/RU2745601C2/ru not_active Application Discontinuation
- 2009-12-09 KR KR1020117015821A patent/KR101762966B1/ko active Active
- 2009-12-09 EP EP20197506.7A patent/EP3792282A1/en active Pending
- 2009-12-09 LT LTEP16162699.9T patent/LT3072906T/lt unknown
- 2009-12-09 PE PE2011001179A patent/PE20120342A1/es active IP Right Grant
- 2009-12-09 IL IL264316A patent/IL264316B2/en unknown
- 2009-12-09 AU AU2009324371A patent/AU2009324371B2/en active Active
- 2009-12-09 NZ NZ592918A patent/NZ592918A/xx unknown
- 2009-12-09 PL PL16162699T patent/PL3072906T3/pl unknown
- 2009-12-09 PL PL09764858.8T patent/PL2376533T3/pl unknown
- 2009-12-09 SI SI200931459A patent/SI2376533T1/sl unknown
- 2009-12-09 CN CN202111066425.9A patent/CN114225022A/zh active Pending
- 2009-12-09 MY MYPI2014002791A patent/MY166050A/en unknown
- 2009-12-09 HR HRP20160754TT patent/HRP20160754T1/hr unknown
- 2009-12-09 DK DK09764858.8T patent/DK2376533T3/en active
- 2009-12-09 DK DK16162699.9T patent/DK3072906T3/da active
- 2009-12-09 KR KR1020177009939A patent/KR20170044211A/ko not_active Ceased
- 2009-12-09 CN CN200980149644.4A patent/CN102245639B/zh active Active
- 2009-12-09 MA MA33984A patent/MA33023B1/fr unknown
- 2009-12-09 RU RU2011127913/15A patent/RU2563179C2/ru active
- 2009-12-09 PT PT97648588T patent/PT2376533T/pt unknown
- 2009-12-09 HU HUE16162699A patent/HUE056626T2/hu unknown
- 2009-12-09 HR HRP20211899TT patent/HRP20211899T1/hr unknown
- 2009-12-09 ES ES16162699T patent/ES2900624T3/es active Active
- 2009-12-09 WO PCT/EP2009/066675 patent/WO2010066762A1/en not_active Ceased
2011
- 2011-05-09 ZA ZA2011/03362A patent/ZA201103362B/en unknown
- 2011-05-10 TN TN2011000229A patent/TN2011000229A1/fr unknown
- 2011-05-16 IL IL212922A patent/IL212922B/en active IP Right Grant
- 2011-06-09 CL CL2011001406A patent/CL2011001406A1/es unknown
- 2011-06-10 CO CO11072271A patent/CO6361952A2/es not_active Application Discontinuation
- 2011-07-08 EC EC2011011192A patent/ECSP11011192A/es unknown
2012
- 2012-08-15 US US13/586,185 patent/US8623367B2/en active Active
2015
- 2015-07-01 JP JP2015132999A patent/JP2015231997A/ja not_active Withdrawn
2016
- 2016-06-30 CY CY20161100603T patent/CY1117735T1/el unknown
- 2016-07-11 SM SM201600222T patent/SMT201600222B/it unknown
2018
- 2018-05-29 JP JP2018102715A patent/JP2018168158A/ja not_active Withdrawn
2020
- 2020-07-16 US US16/930,475 patent/US20200384108A1/en not_active Abandoned
- 2020-08-06 JP JP2020133477A patent/JP7286595B2/ja active Active
- 2020-08-10 IL IL276622A patent/IL276622A/en unknown
2021
- 2021-12-07 CY CY20211101069T patent/CY1124844T1/el unknown
2023
- 2023-05-24 JP JP2023085464A patent/JP2023109938A/ja active Pending
2025
- 2025-10-30 JP JP2025183240A patent/JP2026021446A/ja active Pending

Also Published As

Publication number	Publication date
JP2026021446A (ja)	2026-02-10
KR20170044211A (ko)	2017-04-24
CA2745938C (en)	2018-04-24
IL212922B (en)	2019-02-28
JP2023109938A (ja)	2023-08-08
JP6143416B2 (ja)	2017-06-07
JP2020203889A (ja)	2020-12-24
KR101762966B1 (ko)	2017-07-31
RU2011127913A (ru)	2013-01-20
DK3072906T3 (da)	2021-12-13
WO2010066762A1 (en)	2010-06-17
SMT201600222B (it)	2016-08-31
JP2018168158A (ja)	2018-11-01
IL264316B1 (en)	2023-09-01
CN102245639B (zh)	2014-12-24
HUE056626T2 (hu)	2022-02-28
IL264316B2 (en)	2024-01-01
US20110236398A1 (en)	2011-09-29
SI3072906T1 (sl)	2022-01-31
HRP20160754T1 (hr)	2016-08-12
MY157772A (en)	2016-07-29
NZ592918A (en)	2012-12-21
ZA201103362B (en)	2012-01-25
CY1124844T1 (el)	2022-11-25
AU2009324371A1 (en)	2011-06-23
BRPI0922730A2 (pt)	2018-11-06
CN104399076B (zh)	2021-09-14
RU2563179C2 (ru)	2015-09-20
JP2015231997A (ja)	2015-12-24
ES2900624T3 (es)	2022-03-17
RU2015132431A3 (pt)	2018-12-24
PE20120342A1 (es)	2012-04-24
RU2015132431A (ru)	2018-12-24
LT3072906T (lt)	2021-12-27
CA2745938A1 (en)	2010-06-17
CN102245639A (zh)	2011-11-16
EP3792282A1 (en)	2021-03-17
IL264316A (en)	2019-02-28
IL276622A (en)	2020-09-30
US8623367B2 (en)	2014-01-07
US20200384108A1 (en)	2020-12-10
EP2376533B1 (en)	2016-03-30
AU2009324371B2 (en)	2013-10-10
HUE028408T2 (en)	2016-12-28
TN2011000229A1 (en)	2012-12-17
HK1159130A1 (zh)	2012-07-27
CN104399076A (zh)	2015-03-11
ES2579835T3 (es)	2016-08-17
MY166050A (en)	2018-05-22
JP7286595B2 (ja)	2023-06-05
SI2376533T1 (sl)	2016-07-29
HRP20211899T1 (hr)	2022-03-04
CO6361952A2 (es)	2012-01-20
ECSP11011192A (es)	2011-08-31
KR20120009421A (ko)	2012-01-31
PL2376533T3 (pl)	2016-09-30
PT3072906T (pt)	2021-12-14
EP3072906A1 (en)	2016-09-28
US20120315285A1 (en)	2012-12-13
JP2012511540A (ja)	2012-05-24
CY1117735T1 (el)	2017-05-17
MX2011006242A (es)	2011-06-24
RU2745601C2 (ru)	2021-03-29
CN114225022A (zh)	2022-03-25
IL212922A0 (en)	2011-07-31
PL3072906T3 (pl)	2022-01-24
MA33023B1 (fr)	2012-02-01
EP2376533A1 (en)	2011-10-19
EP2196476A1 (en)	2010-06-16
DK2376533T3 (en)	2016-06-27
EP3072906B1 (en)	2021-09-08
CL2011001406A1 (es)	2012-03-30

Publication	Publication Date	Title
SMT201600222B (it)	2016-08-31	Formulazione di anticorpi
EP2358392A4 (en)	2012-08-29	ANTIBODY FORMULATION
BRPI1006519A2 (pt)	2016-08-09	formulação de anticorpos
IL287311A (en)	2021-12-01	Antibodies and processes for preparing the same
DK2459167T3 (da)	2013-06-03	SUBKUTAN ANTI-HER2-antistofformulering
IL212175B (en)	2019-08-29	Muc1* antibodies
BRPI0820819A2 (pt)	2015-06-16	Formulação de anticorpos
EP2241578A4 (en)	2012-09-12	Anti-cldn6 antibody
EP2254911A4 (en)	2011-10-19	HUMANIZED ANTI-C5aR ANTIBODIES
BRPI0917888A2 (pt)	2014-02-25	Formulação de anticorpo líquida estável
EP2262831A4 (en)	2012-07-25	ANTI-properdin antibody
BRPI0906877A2 (pt)	2015-07-28	Anticorpos anti-trkb aperfeiçoados
HRP20171011T1 (hr)	2017-09-22	ANTI-eMET ANTITIJELO
PT2170388T (pt)	2017-01-04	Formulações de anticorpos anti-cd20
EP2207803A4 (en)	2010-11-24	Cd9-specific human antibodies
EP2351777A4 (en)	2012-11-21	ANTI-MUC1 ANTIBODIES
PT2406284T (pt)	2016-09-29	Anticorpos anti-bcma
EP2332698A4 (en)	2012-01-04	ROBOT HAND
BRPI0912213A2 (pt)	2015-10-06	preparação cosmética
EP2380713A4 (en)	2014-01-22	ROBOT HAND
EP2383082A4 (en)	2014-06-04	ROBOT HAND
BRPI1009465A2 (pt)	2015-08-18	Formulação
BRPI0909633A2 (pt)	2015-09-22	anticorpos anti-tyrp1
PT2260053E (pt)	2014-08-29	Análogos de oxitocina
EP2300776A4 (en)	2013-11-27	CALIBRATION OF DETONATORS